Background
==========

HIV-1 infection induces strong and broadly directed HLA class I restricted T cell responses for which specific epitopes and restricting HLA class I alleles have been associated with relative in vivo viral control \[[@B1]\]. The bulk of the anti-viral CTL response appears to be disproportionately HLA-B restricted, but the relative contribution of targeted viral regions and restricting HLA molecules on the effectiveness of these responses remains unclear \[[@B2]-[@B5]\]. In addition, the impact of HIV-1 sequence diversity on the effectiveness of virus-specific T cell immunity in vivo is unclear, as functional constraints of escape variants, codon-usage at individual protein positions, T cell receptor (TCR) plasticity and functional avidity and cross-reactivity potential may all contribute to the overall antiviral activity of a specific T cell response \[[@B6]-[@B13]\]. Of note, T cell responses to Gag have most consistently been associated with reduced viral loads in both clade B and clade C infected cohorts \[[@B14]-[@B16]\]; however, the specific regions in Gag responsible for this effective control remain poorly defined. In addition, it is unclear whether the relative benefit of Gag is due to any other specific characteristic of this protein, such as rapid antigen-representation upon infection, protein expression levels, amino acid composition and/or inherently greater processability and immunogenicity, particularly in the context of selected HLA class I alleles \[[@B17],[@B18]\]. Thus, concerns remain that a purely Gag-based vaccine might mainly benefit those people with a particular HLA genotype and will not take advantage of potentially beneficial targets outside of Gag \[[@B4],[@B16],[@B17],[@B19]\]. In addition, CTL escape and viral fitness studies have focused largely on Gag-derived epitopes presented in the context of protective HLA class I alleles such as HLA-B27 and -B57 \[[@B7],[@B20],[@B21]\], yielding results that may not be generalizable to the genetically diverse majority of the human population. Furthermore, many studies have focused on immunodominant targets only, despite some studies in HIV-1 and SIV infection demonstrating a crucial contribution of sub-dominant responses to targets outside of Gag to the effective in-vivo viral control \[[@B4],[@B22]\]. Thus, the current view on what may constitute a protective cellular immune response to HIV-1 is likely biased towards a immunodominant responses and those restricted by frequent HLA class I alleles and HLA alleles associated with superior disease outcome.

To overcome these potential limitations, the design of an effective and broadly applicable HIV-1 vaccine should to be based on information gained through comprehensive analyses that extend across large portions of the population\'s HLA class I heterogeneity. Here we focus on three cohorts totaling more than 950 untreated, chronically HIV-1 infected individuals with clade B and C infections, from which responses to certain regions of the viral genome and specific T cell response patterns emerge as correlates of viral control. Importantly, the analyses identify functional properties unique to these responses and control for the impact of HLA class I alleles known to be associated with superior control of HIV-1 infection, thus providing vaccine immunogen sequence candidates with potential usefulness in a broadly applicable HIV-1 vaccine.

Methods
=======

Cohorts
-------

A HIV clade B infected cohort of 223 chronically infected, treatment naïve individuals was recruited and tested at IMPACTA in Lima, Peru. The majority (78%) of enrollees were male and all recruited individuals considered themselves to be of a mixed Amerindian ethnicity \[[@B14]\]. The cohort had a median viral load 37,237 copies/ml (range \< 50- \> 750,000) and a median CD4 count of 385 cell/ul (range170-1151). A second clade B infected cohort was established at the HIV-1 outpatient clinic \"Lluita contra la SIDA\" at Hospital Germans Trias i Pujol in Badalona (Barcelona, Spain) consisting of 48 treatment-naïve subjects with viral loads below 10,000 and CD4 cell counts \> 350 cells/mm^3^(\"controllers\", n = 24) or above 50,000 copies/ml and CD4 cell counts \< 350 cells/mm^3^(\"non-controllers\", n = 24). The HIV-1 clade C infected cohort has been described in the past and consisted of 631 treatment naïve South African with a median viral load of 37,900 copies/ml (range \< 50-\> 750,000) and a median CD4 count of 393 cells/ul (range 1-1378) \[[@B16]\]. An additional 78 from a recently published cohort in Boston were included in the analyses of functional avidities \[[@B23]-[@B29]\]. HLA typing was performed as previously described using SSP-PCR \[[@B30]\]. For Hepitope and FASS analyses, 4digit typing was used for the Lima cohort and 2-digit typing for the Durban cohort. Protocols were approved in Lima by the IMPACTA Human Research Committee, in Durban by the Ethical Committee of the Nelson R. Mandela School of Medicine at the University of KwaZulu-Natal and in Barcelona by the Human Research Committee at Hospital Germans Trias i Pujol. All subjects provided written informed consent.

Peptide test set and ELISpot assay: Previously described peptide sets matching HLA-clade B and C consensus sequences were used in all experiments for which the OLP-specific entropies have been calculated in the past, based on available sequence datasets \[[@B31]-[@B33]\] and <http://www.hiv.lanl.gov/content/immunology/hlatem/index.html>. The peptides were clade-specific sets of adapted 18mers, overlapping by 11 residues designed using the PeptGen tool available at the Los Alamos HIV database <http://www.hiv.lanl.gov/content/sequence/PEPTGEN/peptgen.html>. The individual OLP in the peptide sets for clade B and clade C had all the same starting and ending position relative to the source protein and follow the same numbering across the entire viral proteome for both clades. Peripheral blood mononuclear cells (PBMCs) were separated from whole blood by density centrifugation and used directly to test for CD8^+^T cell responses in vitro. IFN-γ ELISpot assays were performed as described previously, using Mabtech antibodies (Mabtech, Stockholm, Sweden) and a matrix format that allowed simultaneous testing of all 410 overlapping (OLP) peptides in the respective test set \[[@B14]\]. Thresholds for positive responses were defined as: exceeding 5 spots (50 SFC/10^6^) per well and exceeding the mean of negative wells plus 3 standard deviation or three times the mean of negative wells, whichever was higher. Stimulation with PHA was used as a positive control in all ELISpot assays.

Definition of functional avidity
--------------------------------

Responses targeting 18 mer OLP in HIV-1 Gag p24 were assessed for their functional avidity using OLP-specific sets of 10 mer peptides overlapping by 9 residues that span the 18 mer peptide sequence. Functional avidity was defined as the peptide concentration needed to elicit half maximal response rates in the ELISpot assay and was calculated as a sigmoidal dose response curve fit using GraphPad Prism software \[[@B13]\].

*In vitro*viral replication inhibition assay
--------------------------------------------

A double mutant virus containing a Nef M20A and Integrase G140S/Q148H Raltegravir (integrase inhibitor) resistance mutations was tested for replication in CD4 T cells in the presence or absence of autologous T cell lines targeting protective or non-protective OLP. Use of the Raltegravir-resistant virus allows to prevent potential replication of autologous virus in the inhibition assays \[[@B28]\], excludes potential negative impacts on antigen processing or CTL functions attributed to protease inhibitors \[[@B34]\] and avoids overlap between the resistance mutations sites (i.e. G140S/Q148H) and location of beneficial and non-beneficial OLP sequences. In brief, the p83-10 plasmid containing mutations for a methionine to alanine substitution at position 20 of the Nef protein and the p83-2 plasmid engineered to contain the G140S and Q148H mutations in the integrase were combined to produce a virus that is replication competent, highly resistant to Raltegravir and does not downregulate HLA class I in infected cells \[[@B35],[@B36]\]. Although not entirely physiological, this approach was chosen to potentially increase the signal in the in vitro inhibition assay, even when responses were restricted by Nef-sensitive HLA class I alleles. Plasmids were co-transfected into MT4 cells and virus was harvested after 7 days \[[@B35],[@B37],[@B38]\]. Autologous CD4 cells were enriched by magnetic beads isolation (Miltenyi) and expanded for 3 days using a bi-specific anti-CD3/8 antibody and IL-2 containing medium (50 IU r-IL2) before infecting them at multiplicities of infection (MOI) between 0.01 and 1. Effector cells were obtained by stimulating PBMC with either beneficial or non-beneficial OLP for 12 days before isolating specific OLP-reactive cells by IFN-γ capture assay according to manufacturers\' instructions (Miltenyi, Bergisch Gladbach, Germany). The effector T cells were analyzed by flow cytometry for the specificity to their respective targets after capture assay and quantified to adjust effector-to-target ratios. Since the NL4-3 backbone sequence differed in several positions in beneficial and non-beneficial OLP, the epitope specificity was predicted based on the HLA class I genotype of the tested individual and responses confirmed to efficiently recognize variant sequences in the NL4-3 backbone sequence. Culture supernatant was harvested and replaced by Raltegravir containing medium 0.05 μg/ml after 72 h. Levels of Gagp24 in the culture supernatant were determined by ELISA as described \[[@B39]\].

Statistical Analyses
--------------------

Statistical analyses were performed using Prism Version 5 and R Statistical Language \[[@B40]\]. Results are presented as median values unless otherwise stated. Tests included ANOVA, non-parametric Mann-Whitney test (two-tailed) and Spearman rank test. The significance of differences in viral load distribution between OLP-responders and OLP-non-responders was assessed by a two-sided Student\'s T Test with multiple tests addressed using, instead of a Bonferroni correction, a q-value approach to compensate for multiple comparisons \[[@B39]\]. The multivariate analysis was based on a novel multivariate combined regression method known as FASS, a forward selection method combined with all-subsets regression \[[@B41]-[@B43]\]. Briefly, the FASS approach works by iteratively performing the following procedure: Let \'V\' be the set of all variables and \'M\' be the set of variables included in a model. In the first step, those variables that are not already in the model are divided into equal-sized blocks of variables (the last block may have less than \'g\' variables). Then, for each block of variables, \'m\' is a new estimated and evaluated model using the Bayesian Information Criterion (BIC). The best model \'m\' according to its BIC is retained and the procedure starts all over again until in one step or more the model is not improved.

Results
=======

HIV-1-specific T cell responses targeting conserved regions are associated with lower viral loads
-------------------------------------------------------------------------------------------------

In a first analysis, HIV-1-specific T cell responses were assessed in a cohort of 223 HIV-1 clade B infected individuals recruited in Lima, Peru using IFNg ELISpot assays and a previously described set of 410 clade B overlapping peptides (OLP) \[[@B14],[@B31]\]. For each OLP, a protective ratio (PR) was calculated as the ratio of the median viral loads between OLP non-responders and OLP responders, such that OLP with PR \> 1 were reflective of OLP predominantly targeted by individuals with reduced viral loads. OLP-specific PR were a) compared between OLP spanning the different viral proteins and b) correlated with the viral sequence heterogeneity in the region covered by the OLP. The data showed highest median PR values for OLP spanning the Gag protein sequence, whereas Nef, Env and Tat had the lowest median PR values (Figure [1A](#F1){ref-type="fig"}, p \< 0.0001, ANOVA). A protein-subunit-breakdown of PR values showed the p15 subunit of Gag and RT in Pol to score less favorable than the remainder of the respective proteins (Figure [1B](#F1){ref-type="fig"}, p = 0.0032 and p = 0.0025, respectively). While these data confirm the association between HIV-1 Gag-specific responses and lower viral loads, it is important to note that all proteins contained OLP with PR \> 1, suggesting that some beneficial responses can be located outside of Gag; data that has not emerged from any of the previous studies linking Gag responses to relative viral control. At the same time, all proteins contained OLP with PR \< 1, indicating that proteins considered overall beneficial may contain non-beneficial regions as well. In addition, when the OLP-specific PR was compared to the sequence entropy of the region spanned by the individual OLP, a significant negative correlation between PR and entropy was observed (p = 0.0028, r = -0.15; Figure [1C](#F1){ref-type="fig"}). Although rarely targeted OLP may have introduced statistically less robust data points in this comparison and caused a wide scatter of data points, the results show a relative absence of OLP with high entropy and high PR values, suggesting that responses to more variable regions are less effective in mediating in vivo viral control.

![**Localization and conservation of beneficial and non-beneficial OLP in HIV-1 clade B and C cohorts**. Total HIV-1-specific T cell responses were assessed in a cohort of 223 chronically HIV clade B infected, untreated individuals in Lima, Peru (**graphs A-C**) and in 631 chronically HIV clade C infected, untreated individuals in Durban, South Africa (**graphs D-F**) using peptide test sets of 410 18 mer overlapping peptides (OLP) spanning the consensus B and C sequences, respectively \[[@B2],[@B31]\]. For each OLP, the protective ratio (PR, defined as \"the ratio of the log median viral load in OLP non-responders divided by log median viral load in OLP responders\") was determined. Each symbol represents an individual OLP, grouped either by (**A, D**) proteins or (**B, E**) protein-subunits for OLP located in Gag, Pol and Env (p-values in A, D based on ANOVA, in B, E on Mann-Whitney by pariwise comparing the different protein subunits, red lines indicating median PR values). In (**C and F**), the OLP-specific entropy (a measure of the viral diversity in the region the OLP spans) is compared to the OLP-specific PR and shows an inverse association between the sequence conservation and PR (Spearman rank).](1479-5876-9-208-1){#F1}

To assess whether the above observations would also hold true outside of clade B infection, the same analyses were conducted in a cohort of 631 clade C HIV-1 infected subjects enrolled in Durban, South Africa and tested for responses against a clade C consensus OLP sequence as described previously \[[@B33]\]. As in clade B infection, the OLP specific PR values were highest for OLP spanning Gag without any significant differences between the Gag and Pol protein subunits (Figure [1D](#F1){ref-type="fig"} and [1E](#F1){ref-type="fig"}). As in the clade B cohort, the PR values were negatively correlated with the OLP-specific entropy (p = 0.0323, Figure [1F](#F1){ref-type="fig"}), confirming the findings in the clade B cohort and further pointing towards the importance of targeting conserved segments of the viral proteome for effective in vivo viral control.

Identification of individual beneficial OLP sequences in clade B and C infection
--------------------------------------------------------------------------------

In order to identify individual OLP that were significantly more frequently targeted in individuals with relative viral control and to compare the beneficial OLP in clade B and C infection, the viral load distribution in OLP-responders and non-responders was analyzed individually for each OLP. For the clade B cohort in Peru, the analyses yielded 43 OLP sequences for which the median viral load differed between the two groups with an uncorrected p-value of \< 0.05. Of these 43 OLP, 26 were OLP with a PR \> 1 (referred to as \"beneficial\" OLP), and 17 OLP with a PR \< 1 (\"non-beneficial\" OLP, Table [1](#T1){ref-type="table"}). The distribution of OLP with PR \> 1 among viral proteins was biased towards Gag and Pol, while Env produced exclusively OLP with PR \< 1 (Figure [2A](#F2){ref-type="fig"}).

###### 

Beneficial and non-beneficial OLP identified in Lima clade B cohort (p \< 0.05)

  -----------------------------------------------------------------------------------------------------------------
  OLP \#   Protein   Sub-unit   OLP clade B\         Median viral\   Median viral\    Protective Ratio\   p-value
                                consensus\           load in OLP\    load in OLP\     (PR)\*              
                                sequence             responders      non-responders                       
  -------- --------- ---------- -------------------- --------------- ---------------- ------------------- ---------
  3        Gag       p17        EKIRLRPGGKKKYKLKHI   22947           39014            **1.053**           0.037

  6        Gag       p17        ASRELERFAVNPGLL      15380           43189            **1.107**           0.001

  7        Gag       p17        ERFAVNPGLLETSEGCR    25939           38974            **1.040**           0.049

  10       Gag       p17        QLQPSLQTGSEELRSLY    16285           37237            **1.085**           0.031

  12       Gag       p17        SLYNTVATLYCVHQRIEV   23855           37113            **1.044**           0.037

  23       Gag       p24        AFSPEVIPMFSALSEGA    22947           37113            **1.048**           0.036

  31       Gag       p24        IAPGQMREPRGSDIA      3563            35483            **1.281**           0.028

  34       Gag       p24        STLQEQIGWMTNNPPIPV   6127            37360            **1.207**           0.002

  48       Gag       p24        ACQGVGGPGHKARVLAEA   12975           35755            **1.107**           0.041

  60       Gag       p15        GKIWPSHKGRPGNFLQSR   16266           36434            **1.083**           0.044

  75       Nef       \-         WLEAQEEEEVGFPVRPQV   13407           37360            **1.108**           0.026

  76       Nef       \-         EVGFPVRPQVPLRPMTYK   59618           29855            0.937               0.001

  84       Nef       \-         NYTPGPGIRYPLTFGWCF   55402           30538            0.945               0.006

  85       Nef       \-         RYPLTFGWCFKLVPV      69890           29903            0.924               0.002

  90       Nef       \-         SLHGMDDPEKEVLVWKF    89687           32650            0.911               0.042

  159      Pol       Pro        KMIGGIGGFIKVRQYDQI   14736           36434            **1.094**           0.020

  160      Pol       Pro        FIKVRQYDQILIEICGHK   3682            35755            **1.277**           0.031

  161      Pol       Pro        QILIEICGHKAIGTVLV    9117            35483            **1.149**           0.050

  163      Pol       Pro        LVGPTPVNIIGRNLLTQI   25965           45637            **1.055**           0.007

  171      Pol       RT         LVEICTEMEKEGKISKI    1865            35483            **1.391**           0.014

  181      Pol       RT         LDVGDAYFSVPLDKDFRK   65858           32871            0.937               0.041

  195      Pol       RT         LRWGFTTPDKKHQKEPPF   5624            37113            **1.219**           0.006

  196      Pol       RT         DKKHQKEPPFLWMGYELH   10103           35483            **1.136**           0.044

  210      Pol       RT         EIQKQGQGQWTYQIY      18155           35483            **1.068**           0.045

  222      Pol       RT         PPLVKLWYQLEKEPIVGA   412599          34640            0.808               0.030

  230      Pol       RT         IHLALQDSGLEVNIV      85102           34117            0.919               0.030

  237      Pol       RT         VYLAWVPAHKGIGGNEQV   85102           34117            0.919               0.029

  240      Pol       RT         SAGIRKVLFLDGIDKA     116902          32761            0.891               0.019

  269      Pol       Int        TKELQKQITKIQNFRVYY   6629            35755            **1.192**           0.030

  270      Pol       Int        TKIQNFRVYYRDSRDPLW   18171           37360            **1.073**           0.019

  271      Pol       Int        YYRDSRDPLWKGPAKLLW   25939           35755            **1.032**           0.043

  276      Pol       Int        KIIRDYGKQMAGDDCVA    6629            35755            **1.192**           0.021

  279      Vpr       \-         GPQREPYNEWTLELLEEL   60222           32650            0.944               0.042

  307      Env       Gp120      DLNNNTNTTSSSGEKMEK   179419          34117            0.863               0.044

  311      Env       Gp120      IRDKVQKEYALFYKLDVV   179419          32871            0.860               0.008

  314      Env       Gp120      YRLISCNTSVITQACPKV   58206           31273            0.943               0.008

  315      Env       Gp120      SVITQACPKVSFEPIPIH   61011           32871            0.944               0.034

  320      Env       Gp120      TNVSTVQCTHGIRPVV     341587          34640            0.820               0.034

  355      Env       Gp120      VAPTKAKRRVVQREKRAV   161602          34117            0.870               0.042

  399      Env       Gp41       VIEVVQRACRAILHIPRR   388089          34640            0.812               0.026

  405      Vif       \-         VKHHMYISGKAKGWFYRH   16458           37237            **1.084**           0.021

  406      Vif       \-         GKAKGWFYRHHYESTHPR   16458           37237            **1.084**           0.022

  424      Vif       \-         TKLTEDRWNKPQKTKGHR   10319           36434            **1.137**           0.014
  -----------------------------------------------------------------------------------------------------------------

\* PR values in bold indicate PR \> 1, i.e. OLP-responses seen more frequently in individuals with reduced viral loads

![**Genome distribution, entropy and RT localization of OLP with significant impact on viral loads in HIV-1 clade B and C infection**: The distribution of OLP with significantly elevated or reduced PR across the viral proteome is shown in **A)**for clade B infection (cut-off uncorrected p-value of p \< 0.05) and in **B)**for clade C infection (cut-off q \< 0.2). The entropy of beneficial and non-beneficial clade B OLP is compared in **C)**while in **D)**, the entropy of beneficial OLP in HIV clade C Gag is compared to the remainder of Gag OLP (p-values based on Mann Whitney, red lines indicating median sequence entropies). In E and F, protein structures for HIV-1 reverse transcriptase (Protein databank structure ID 3IG1) were loaded into the Los Alamos HIV Database \"protein feature accent\" tool <http://www.hiv.lanl.gov/content/sequence/PROTVIS/html/protvis.html> and locations of beneficial RT OLP identified in clade B (Table 1) and in clade C (Table 2) marked by red highlights.](1479-5876-9-208-2){#F2}

The same analyses were repeated for the clade C cohort in Durban, which due to its larger size allowed to apply more stringent statistical criteria to identify beneficial and non-beneficial OLP. To compensate for multiple statistical comparisons, we employed a previously described false-discovery rate approach \[[@B39]\], resulting in the identification of 33 clade C OLP with q-values of \< 0.2 (i.e. OLP with significantly different viral load distributions between OLP-responders and non-responders with a false positive discovery rate (q-value) of 20%). The 33 OLP identified were comprised of 22 beneficial OLP and 11 non-beneficial OLP, with the beneficial OLP being again located in Gag, Pol and Vif, similar to what was seen in the clade B cohort (Figure [2B](#F2){ref-type="fig"}).

In both cohorts, the total breadth and magnitude of responses did not correlate with viral loads as reported for parts of these cohorts in the past \[[@B14],[@B16]\]. The OLP with significant differences in median viral loads (43 OLP in clade B and 33 OLP in clade C, Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, respectively, i.e. \"scoring OLP\"), were more often targeted in their respective cohort than OLP that did not score with a significant difference in viral loads (p = 0.0015 Lima; p \< 0.0001 Durban). However, beneficial and non-beneficial OLP were equally frequently targeted in either cohort. Also, there was no difference in the median magnitude of the OLP-specific responses, regardless whether it was a beneficial, non-beneficial or not-scoring OLP (all p \> 0.7, data not shown). Finally, there was no correlation between the number of total OLP responses (against all 410 OLP) and the magnitude of responses to beneficial OLP in either cohort, indicating that the strength of beneficial OLP responses was not diminished by other responses to the rest of the viral proteome.

###### 

Beneficial and non-beneficial OLP identified in Durban clade C cohort (q \< 0.2)

  -----------------------------------------------------------------------------------------------------------------------------
  OLP \#   Protein   Sub-unit   OLP clade C\           Median viral\   Median viral\    Protective Ratio\   p-value   Q-value
                                consensus\             load in OLP\    load in OLP\     (PR)\*                        
                                sequence               responders      non-responders                                 
  -------- --------- ---------- ---------------------- --------------- ---------------- ------------------- --------- ---------
  3        Gag       p17        EKIRLRPGGKKHYMLKHL     18,700          45,100           **1.09**            0.0002    0.0006

  6        Gag       p17        ASRELERFALNPGLL        6,570           44,100           **1.22**            0.0000    0.0000

  7        Gag       p17        ERFALNPGLLETSEGCK      5,270           43,900           **1.25**            0.0000    0.0000

  22       Gag       p24        WVKVIEEKAFSPEVIPMF     8,360           42,850           **1.18**            0.0000    0.0000

  25       Gag       p24        GATPQDLNTMLNTVGGH      24,450          45,200           **1.06**            0.0021    0.0263

  26       Gag       p24        NTMLNTVGGHQAAMQMLK     5,310           39,600           **1.23**            0.0061    0.0766

  27       Gag       p24        GGHQAAMQMLKDTINEEA     9,715           42,100           **1.16**            0.0015    0.0170

  29       Gag       p24        AAEWDRLHPVHAGPIA       19,700          40,900           **1.07**            0.0045    0.0544

  31       Gag       p24        IAPGQMREPRGSDIA        6,480           38,950           **1.20**            0.0146    0.1478

  33       Gag       p24        SDIAGTTSTLQEQIAWM      11,650          40,900           **1.13**            0.0025    0.0318

  37       Gag       p24        WIILGLNKIVRMYSPVSI     9,360           44,100           **1.17**            0.0004    0.0018

  39       Gag       p24        SILDIKQGPKEPFRDYV      2,630           38,250           **1.34**            0.0182    0.1838

  41       Gag       p24        YVDRFFKTLRAEQATQDV     22,150          44,100           **1.07**            0.0020    0.0263

  42       Gag       p24        LRAEQATQDVKNWMTDTL     16,480          40,900           **1.09**            0.0078    0.0935

  55       Gag       p15        HIARNCRAPRKKGCWK       7,550           39,700           **1.19**            0.0092    0.1047

  59       Gag       p15        RQANFLGKIWPSHKGR       9,840           42,200           **1.16**            0.0046    0.0539

  60       Gag       p15        GKIWPSHKGRPGNFLQSR     6,130           39,700           **1.21**            0.0066    0.0799

  63       Gag       p15        TAPPAESFRFEETTPAPK     6,040           38,950           **1.21**            0.0093    0.1020

  116      Tat       Tat        TKGLGISYGRKKRRQRRS     109,000         36,700           0.91                0.0033    0.0410

  178      Pol       RT         FWEVQLGIPHPAGLKKKK     258,000         37,300           0.84                0.0033    0.0384

  181      Pol       RT         LDVGDAYFSVPLDEDFRK     7,100           38,950           **1.19**            0.0186    0.1832

  190      Pol       RT         RAQNPEIVIYQYMDDLYV     84,900          34,700           0.92                0.0043    0.0555

  199      Pol       RT         TVQPIQLPEKDSWTVNDI     6,700           38,300           **1.20**            0.0198    0.1926

  216      Pol       RT         QKIAMESIVIWGKTPKFR     18,150          43,000           **1.09**            0.0026    0.0317

  239      Pol       RT         QVDKLVSSGIRKVLFL       373,200         37,700           0.82                0.0205    0.1937

  253      Pol       Int        PAETGQETAYFILKLAGR     92,800          35,400           0.92                0.0082    0.0954

  265      Pol       Int        AVFIHNFKRKGGIGGYSA     63,650          33,800           0.94                0.0178    0.1826

  283      Vpr       \-         GLGQYIYETYGDTWTGV      78,000          35,600           0.93                0.0126    0.1302

  284      Vpr       \-         ETYGDTWTGVEALIRIL      85,050          35,200           0.92                0.0099    0.1034

  312      Env       Gp120      YALFYRLDIVPLNENNSSEY   270,000         37,700           0.84                0.0208    0.1915

  365      Env       Gp41       GIKQLQTRVLAIERYLK      151,000         34,700           0.88                0.0001    0.0002

  393      Env       Gp41       LLGRSSLRGLQRGWEALKYL   750,000         37,450           0.78                0.0007    0.0041

  417      Vif       \-         CFADSAIRKAILGHIV       1,110           38,200           **1.50**            0.0178    0.1891
  -----------------------------------------------------------------------------------------------------------------------------

\* PR values in bold indicate PR \> 1, i.e. OLP-responses seen more frequently in individuals with reduced viral loads

In the clade B cohort, the 26 beneficial and 17 non-beneficial OLP showed a significant difference in their median entropy (p = 0.0327, Figure [2C](#F2){ref-type="fig"}), in line with the overall negative association between higher PR and lower sequence entropy seen in the comprehensive screening including the entire 410 OLP set (Figure [1C](#F1){ref-type="fig"}). While this comparison was not significant in clade C infection, a detailed look at Gag showed that beneficial Gag clade C OLP had a lower entropy values than the rest of the Gag OLP, suggesting that targeting of the most conserved regions even in Gag provided particular benefits for viral control (Figure [2D](#F2){ref-type="fig"}, p = 0.0172). These beneficial OLP were also more frequently targeted (median of 36 responders) compared to the rest of Gag OLP (median 12 responders, p = 0.0099), likely reflecting the high epitope density in these regions \[[@B33],[@B44]\].

Finally, the two cohorts showed a partial overlap in the targeted beneficial and non-beneficial OLP, despite the vastly different HLA genetics in these two populations \[[@B4],[@B31],[@B45],[@B46]\]. As Gag was enriched in beneficial OLP scattered throughout the entire protein sequence, we used the available reverse transcriptase (RT) protein structure to assess whether beneficial responses were targeting structurally related regions of the protein, even though the linear position of beneficial OLP did not precisely match between the two clades. Indeed, superimposing the locations of beneficial OLP in the RT protein indicates that in both clades, beneficial OLP fell in structurally related domains of the RT protein (Figure [2E](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"}). This suggests that despite differences in response patterns between ethnicities and clades, viruses from both clades may be vulnerable to responses targeting the same structural regions of at least some of their viral proteins.

Increased breadth of responses against beneficial OLP is associated with decreasing viral loads, independent of Gag-specificity or the presence of protective HLA class I alleles
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To assess whether individuals targeting more than one beneficial OLP profit from a greater breadth of responses to these targets, subjects in both cohorts were stratified by the number of responses to beneficial OLP and their viral loads compared. In both cohorts, negative correlations between the number of responses to beneficial OLP and viral loads were observed (p \< 0.0001, r = -0.33 for Lima; p \< 0.0001, r = 0.-25 for Durban; data not shown), suggesting that there is a cumulative benefit of responses to these particularly effective targets. Similarly, when individuals in the clade C cohort were grouped based on mounting 1-2, 3-4 or five and more beneficial OLP responses, a gradual reduction in median viral loads was seen. This reduction was close to 20-fold when 5 or more of the 22 beneficial OLP were targeted (median viral load 5,210 copies/ml) compared to individuals without a response (98,800 copies/ml, Figure [3A](#F3){ref-type="fig"}). Importantly, this observation was not driven only by individuals expressing HLA class I alleles associated with relative control of viral replication (including HLA-B27, -B57, -B\*5801, -B63 and -B81) as their exclusion still showed a strong association between increased breadth of responses to beneficial OLP and a gradual suppression of viremia (Figure [3B](#F3){ref-type="fig"}). This was further supported when translating the clade B data from Peru to a second clade B infected cohort in Barcelona, Spain where HIV-1 controllers also mounted a significantly greater proportion of their responses to the beneficial Peruvian OLP compared to the HIV-1 non-controllers (61% vs. 29%, p = 0.0011; Figure [3C](#F3){ref-type="fig"}); this despite the fact that the Barcelona cohort was genetically different and excluded individuals expressing HLA-B27, -B57, -B58 and B63. Thus, despite the frequent targeting of Gag and the inclusion of individuals expressing HLA alleles such as HLA-B\*5701 and -B\*5801 in the two larger clade B and C cohorts, the present data identify regions of the viral genome that serve as the targets of an effective host T cell response, largely independent of the presence of HLA alleles known to influence HIV-1 viral replication.

![**Increased breadth of responses to beneficial OLP results in gradually reduced viral loads and is independent of cohort and HLA-B27, -57, -B58, -B81 and -B63**. (**A**) The number of responses to beneficial OLP in the clade C cohort in Durban was determined for each individual and compared to viral loads. An increased breadth of responses to the 22 beneficial OLP was associated with reduced viral loads (ANOVA, p \< 0.0001). (**B**) This association remained equally stable after removing all individuals expressing known beneficial HLA allele (HLA-B27, -B57, -B5801, -B63, -B81) from the analysis (ANOVA, p \< 0.0001). (**C**) The set of 26 beneficial and 17 non-beneficial OLP identified in the clade B infected cohort in Lima, Peru was tested in a second clade B infected cohort in Barcelona. HIV controllers showed a significantly higher focus of responses on the 22 beneficial OLP (61% of all responses to the 43 OLP) while non-controllers reacted predominantly with the non-beneficial OLP (only 29% of all responses targeting beneficial OLP). The Barcelona cohort did not included subject expressing any HLA allele previously associated with relative control of HIV-1 (p = 0.0011, Mann Whitney).](1479-5876-9-208-3){#F3}

PR-values are mediated by individuals with broad HLA heterogeneity
------------------------------------------------------------------

To further assess the contribution of specific HLA class I alleles on the PR of individual OLP, the statistically significant OLP in the clade C cohort were further analyzed. In a first step, median viral loads in the OLP-responder and non-responder groups were compared after excluding individuals with specific HLA class I alleles. If the statistical significance of the comparison was lost, the excluded HLA class I allele was assumed to have significantly contributed to the initially observed elevated or reduced PR value and to restrict a potential CTL epitope in that OLP. In a second step, a \"Hepitope\" analyses <http://www.hiv.lanl.gov/content/immunology/hepitopes> was conducted to identify HLA class I alleles overrepresented in the OLP responder group; providing an alternative approach to identify specific epitopes that may contribute to relative viral control. Together, the two strategies permit to estimate the HLA diversity in the OLP responders and to identify the most likely alleles that restrict the epitope-specific responses to the OLP. Both are important measures when determining the relative usefulness of a selected beneficial OLP in a potential immunogen sequence as it should provide broad HLA coverage. The data from these analyses are summarized for beneficial and non-beneficial OLP in Table [3](#T3){ref-type="table"} and [3](#T3){ref-type="table"}, respectively. The results demonstrate that with a few exceptions, for each OLP, several HLA alleles appeared to be mediating the observed effects as their removal caused the statistical significance to be lost. However, for the most frequent HLA class I alleles, the loss of significance may be due to a reduction in sample size rather than the actual allele, since the exclusion of many allele carriers could reduce the number of OLP responders (and non-responders) sufficiently to lose statistical power. The \"Hepitope\" analysis controlled for this effect and confirmed the obtained results, strongly indicating that responses to beneficial OLP were mediated by responder populations with heterogeneous HLA allele distributions.

###### 

Impact of HLA alleles on the statistical significance of observed PR values (clade C OLP)

  A\) Beneficial OLP (PR \> 1)                                                                                      
  ------------------------------------- ----- ------ -------------------------------------------------------------- --------------------------------------------------
  3                                     Gag   1.09   A30, B42, C17                                                  A30, B08, A03, A74, C17, A43, B42, B07
  6                                     Gag   1.22   *B15*                                                          B49, B82, C14
  7                                     Gag   1.25   \-                                                             B42, C17, B49, A30
  22                                    Gag   1.18   B57, C07                                                       B57, A74, B45, C07, C16, B13
  25                                    Gag   1.06   A30, *B15, C04, C07*                                           B42, C17, B81, B39, A01, C12, C18, A30, B67
  26                                    Gag   1.23   *A02, A23*, A68, *B07, B14, B58, C07, C08*                     C03, B15, A68
  27                                    Gag   1.16   B15, *C07*                                                     B15, A68, C03, C08
  29                                    Gag   1.07   *A68, B15, B58, C02, C03, C06*, C12                            B35, B39, C12, B40, B07, C04
  31                                    Gag   1.2    *A02*, A11, *A23*, A29, *A32, A34, A68, B07*,                  B13, A29, C06, A11
                                                     B13, B15, B42, B44, B58, C04, C06, C07, C17                    
  33                                    Gag   1.13   A02, *A23, B44*, B57, B58, C07                                 B58, B57, A02, C07, C03, A68
  37                                    Gag   1.17   *A30*, B42, *B58*, C17                                         C18, B42, C17, A01, B81
  39                                    Gag   1.34   A02, *A03, A23, A29, A30, A68, A74, B08, B15*,                 A02
                                                     B18, B42, B45, B53, B57, B58, C02, C03, C06,                   
                                                     C07, C08, C16, C17                                             
  41                                    Gag   1.07   *A23, C06*                                                     C03, B14, A68, C08, B15
  42                                    Gag   1.09   *A23, A30, B08, B15, B42*, B53, *B58*, C03, *C04, C07*         B53, C03
  55                                    Gag   1.19   *A02, A24, A29, A30, B07, B15, B39*, B42, *B44*,               B42, B08, C17
                                                     B58, C02, C06, C07, C17                                        
  59                                    Gag   1.16   A02, *A30, B08, B42, B44, B58, C04, C07, C17*                  A02, B13, A29
  60                                    Gag   1.21   A02, *A30, B42, B58, C06*, C07, C17                            A02, B41, C07, C17
  63                                    Gag   1.21   *A02*, A23, *A29, A30, A68, B08, B15, B44, B58*,               A23
                                                     C02, C03, C06, C07                                             
  181                                   Pol   1.19   *A01, A23, A29, A30, A34, A68, A74, B14, B15*,                 B57, C18
                                                     B18, B35, B44, B45, B57, B58, C02, C03, C04,                   
                                                     C06, C07, C08, C16                                             
  199                                   Pol   1.2    *A02, A03*, A23, *A24, A26, A30, A31, A34, A36, A66, A68*,     B53, A23, C04
                                                     A80, B08, B13, B15, B18, B35, B40, B41, B42, B44, B45,         
                                                     B49, B50, B51, B53, B57, B58, B81, C01, C02, C03, C04,         
                                                     *C05, C06, C07, C08, C15, C16, C17*                            
  216                                   Pol   1.09   *A02, A30*, B58, C07, *C17*                                    B53, B58, C07, B57
  417                                   Vif   1.5    *A03, A23, A30, A34*, A36, *A68, B08*, B14, *B15*,             B14, C08, A36
                                                     B44, B53, B58, C03, C04, C06, C08                              
  **B) Non-beneficial OLP (PR \< 1)**                                                                               
  116                                   Tat   0.91   *A02, A34*, B15, *C04*                                         B15, C02
  178                                   Pol   0.84   A03, A68, *B15*, B58, *C04*, C06, *C07*                        A68, C06, B58, B82, A03
  190                                   Pol   0.92   *A03, A30, A66*, B18, *B42*, B45, *B58, C06, C07*              A02, B18, B35, C05, C16, B45, A80, C12, B67, B39
  239                                   Pol   0.82   \-                                                             C05, A03
  253                                   Pol   0.92   *A03*, A68, B15, *B39, B42, B44, B58, C02, C04, C06, C08*,     A68, C03, B15, B07, C15, B41
                                                     C17, C18                                                       
  265                                   Pol   0.94   *A02, A03, A23, A24, A26, A29, A30, A31, A33*,                 B15, C02, A43, A74
                                                     *A34, A66, A68, B07, B08, B14, B15, B27, B40, B41, B42*,       
                                                     *B44, B53, B54, B55, B57, B81, C01*, C02, *C04, C06, C07*,     
                                                     *C12, C17, C18*                                                
  283                                   Vpr   0.93   *A02, A03, A23, A30, A66*, A68, *A74*, B07, *B14, B18, B39*,   A68, C03, B07, C17, B41
                                                     *B41, B42, B45, B57, C02, C04, C07, C08, C15, C17*             
  284                                   Vpr   0.92   *A03, A23, A30, A66*, A68, *A74, B07, B14, B18, B39, B42*,     A68, C03
                                                     *B45, B57, C07, C08, C15, C17*                                 
  312                                   Env   0.84   \-                                                             B08, C07
  365                                   Env   0.88   B58, C06                                                       C06, B58, A43, B45, C16, A66
  393                                   Env   0.78   *A30, B58*, C06                                                A31, C06, B45

1\) in italics HLA alleles that do not emerge from the Hepitope analysis 2) cut-off in Hepitope analyses for p \< 0.05, alleles sorted according to strength of association

Effects of T cell specificity on in vivo viral load are at least as strong as those associated with host HLA genetics
---------------------------------------------------------------------------------------------------------------------

To assess whether specific response patterns and/or HLA combinations could be identified that mediated synergistic or superior control of viral infection in clades B and C, multivariate combined regression analysis was conducted on either OLP only, HLA only or the combination of OLP and HLA variables \[[@B41]-[@B43]\]. The OLP-only analysis for Lima identified 7 OLP of which 4 were associated with lower median viral loads and 3 with increases in viral loads, respectively (Table [4](#T4){ref-type="table"}). Targeting at least one of these beneficial clade B OLP was associated with significantly reduced viral loads (median 11, 079 copies/ml) compared to the subjects who did not target any of these four OLP (median 52, 178 copies/ml; p \< 0.0001, Figure [4A](#F4){ref-type="fig"}). As seen in the univariate analysis (Figure [2C](#F2){ref-type="fig"}), the four beneficial OLP emerging from the Lima FASS analysis were more conserved than the rest of the OLP (median entropy 0.0759 vs. 0.1649, p = 0.0267) or the three non-beneficial OLP (0.0759 vs. 0.1228, p = 0.0571, data not shown). In contrast to OLP-only FASS analysis, only one HLA allele (HLA-C04) emerged from the HLA-only multivariate analysis. The analysis for the combined variables (OLP and HLA) controlled for the potential bias in this result due to more OLP variables (n = 389) than HLA (n = 146) being included in the statistical tests; yet still identified more OLP variables (n = 9) than HLA class I alleles (n = 3). In addition, the relative co-efficients of these associations were stronger for the OLP than the HLA variables, suggesting that T cell specificity influenced viral loads to at least the same degree as host HLA class I genetics. Of note, the identified OLP and HLA variables did not reflect responses to known optimal CTL epitopes, as none of the OLP contained described epitope(s) restricted by any of the identified HLA alleles \[[@B44]\].

###### 

Multivariate analysis of OLP and HLA variables for clade B and C cohorts

  OLP variables only (Lima, clade B)          OLP variables only (Durban, clade C)                                                                    
  ------------------------------------------- --------------------------------------------- ----------------------- ----------------------- --------- --------
  [Beneficial]{.ul}                                                                                                 [Beneficial]{.ul}                 
  OLP.6                                       -0.4591                                       0.0008                  OLP.7                   -0.6256   0
  OLP.31                                      -1.4055                                       0.0002                  OLP.21                  -0.6663   0
  OLP.171                                     -2.5981                                       0                       OLP.22                  -0.4926   0.0006
  OLP.276                                     -1.127                                        0.0007                  OLP.25                  -0.2822   0.0002
                                                                                                                    OLP.27                  -0.4719   0.0053
  [Non-beneficial]{.ul}                                                                                             OLP.33                  -0.3396   0.0024
  OLP.76                                      0.2486                                        0.0067                  OLP.398                 -1.8179   0.0027
  OLP.306                                     3.2968                                        0.0001                  OLP.417                 -1.6535   0.0008
  OLP.411                                     1.3329                                        0.012                                                     
                                                                                                                    [Non-beneficial]{.ul}             
                                                                                                                    OLP.38                  0.9045    0.0022
                                                                                                                    OLP.84                  0.1947    0.0091
                                                                                                                    OLP.116                 0.6156    0.0039
                                                                                                                    OLP.183                 0.661     0.0013
                                                                                                                    OLP.224                 0.2508    0.0036
                                                                                                                    OLP.265                 0.5782    0
                                                                                                                    OLP.365                 0.4911    0.0009
                                                                                                                    OLP.393                 1.2624    0.0013
  **HLA variables only (Lima, clade B)**      **HLA variables only (Durban, clade C)**                                                                
  [Non-beneficial]{.ul}                                                                     [Beneficial]{.ul}                                         
  HLA-C0401                                   0.35652                                       0.00024                 HLA-A74                 -0.3553   0.0025
                                                                                                                    HLA-B13                 -0.6443   0.0004
                                                                                                                    HLA-B57                 -0.5195   0.0007
                                                                                                                    HLA-B81                 -0.3619   0.0015
                                                                                                                    HLA-C12                 -0.6544   0.0001
                                                                                                                    [Non-beneficial]{.ul}             
                                                                                                                    HLA.B.15                0.2506    0.0012
                                                                                                                    HLA.B.18                0.5521    0.0005
                                                                                                                    HLA.C.6                 0.3958    0
                                                                                                                                                      
  **HLA and OLP variables together (Lima)**   **HLA and OLP variables together (Durban)**                                                             
  [Beneficial]{.ul}                                                                                                 [Beneficial]{.ul}                 
  OLP.6                                       -0.5792                                       0                       OLP.6                   -0.4798   0.0023
  OLP.31                                      -1.1607                                       0.0005                  OLP.7                   -0.4528   0.0015
  OLP.171                                     -2.7948                                       0                       OLP.27                  -0.4676   0.0049
  OLP.276                                     -0.9609                                       0.0011                  OLP.59                  -0.4196   0.0115
                                                                                                                    OLP.417                 -1.387    0.0041
  [Non-beneficial]{.ul}                                                                     [Non-beneficial]{.ul}                                     
  OLP.2                                       0.3945                                        0.018                   OLP.148                 2.5215    0.0029
  OLP.237                                     0.7211                                        0.0035                  OLP.183                 0.6108    0.0023
  OLP.288                                     1.5537                                        0.0016                  OLP.393                 1.1442    0.0023
  OLP.311                                     0.7197                                        0.0091                                                    
  OLP.411                                     1.5306                                        0.0024                  [Beneficial]{.ul}                 
                                                                                                                    HLA-A74                 -0.3744   0.0007
  [Beneficial]{.ul}                                                                                                 HLA-B57                 -0.4887   0.0007
  HLA-B1502                                   -1.4688                                       0.0164                  HLA-B81                 -0.3859   0.0004
                                                                                                                    HLA-C12                 -0.6003   0.0002
  [Non-beneficial]{.ul}                                                                                             [Non-beneficial]{.ul}             
                                                                                                                                                      
  HLA-B0801                                   0.66                                          0.0049                  HLA-B15                 0.2797    0.0001
  HLA-C0401                                   0.2894                                        0.0006                  HLA-B18                 0.5316    0.0003
                                                                                                                    HLA-B49                 0.9713    0.0007

\* negative co-efficient values indicate reduction in median viral loads

![**Responses to OLP identified in multi-variate analysis are associated with reduced viral loads**: Response patterns and HLA class I genetics in the clade B cohort in Lima and clade C cohort in Durban were subjected to FASS multivariat analysis \[[@B41]-[@B43]\]. Viral loads in individuals mounting zero vs. at least one response to beneficial OLP identified by the FASS multi-variate analysis were compared for (**A**) the Lima clade B cohort and the (**B**) Durban clade C cohort. The larger data set for the clade C cohort allowed for a further stratification of the responder group by increasing numbers of targeted OLP emerging from the FASS analysis (**C**). A gradually declining median viral load in relation to an increasing breadth of these responses was seen (ANOVA, p \< 0.0001).](1479-5876-9-208-4){#F4}

Results from the clade C cohort in Durban confirmed the clade B findings in Lima as the FASS analyses identified 16 OLP but only 8 HLA variables that had an impact on the individual viral loads. As in Lima, the impact of OLP specificity was at least as strong than HLA genotype (trend for higher coefficients for OLP than HLA; data not shown, p \> 0.05). In addition, targeting at least one of the eight beneficial OLP in Durban was associated with strongly reduced viral loads (p \< 0.0001, Figure [4B](#F4){ref-type="fig"}). This effect was, as in the univariate analysis, additive for more than one response (p \< 0.0001, Figure [4C](#F4){ref-type="fig"}) and included OLP that were, aside from Gag, located in Pol and Vif. Also, the combined (OLP and HLA) analysis suggests the effect of OLP specificity on viral loads to be at least as strong as HLA genetics as 8 OLP and 7 HLA variables were identified. This especially since among the 7 HLA alleles, two (HLA-B57 and HLA-A74) are expressed in linkage disequilibrium \[[@B47]\], further reducing the number of HLA variables with a significant impact on viral loads.

Responses to beneficial OLP are of higher functional avidity and suppress viral replication in vitro more effective than responses to non-beneficial OLP
--------------------------------------------------------------------------------------------------------------------------------------------------------

Functional avidity and the ability to suppress in vitro viral replication have emerged as two potentially crucial parameters of an effective CTL response against HIV-1 \[[@B23]-[@B29]\]. To assess this potential functional characteristic of beneficial CTL populations, we determined the functional avidity of responses to the four beneficial OLP located in Gag p24, a region that has been most consistently associated with eliciting relatively protective CTL responses. As 18 mer peptides are suboptimal test peptides to determine functional avidity, 10 mer overlapping peptide sets were synthesized to cover the four beneficial OLP and all detected responses were titrated. The SD50% was determined for a comparable numbers of responses detected in controllers (n = 21 responses) and non-controllers (n = 24 responses) and showed a statistically significant difference between the two groups (median 3, 448 ng/ml vs. 25, 924 ng/ml, p = 0.0051, Figure [5A](#F5){ref-type="fig"}). This reduced avidity in HIV non-controllers to beneficial OLP could possibly explain why HIV-1 non-controllers did not control their in vivo viral replication despite targeting these regions in some instances and with responses of comparable magnitude as HIV controllers (278 SFC vs 305 SFC/10^6^PBMC, p = 0.55, data not shown).

![**Responses to beneficial OLP are of higher functional avidity and suppress in vitro viral replication more effectively**. (**A**) Responses to the four beneficial OLP located in HIV-1 clade B Gag p24 were retested using a peptide set of 10 mers overlapping by 9 residues. A total of 21 responses in HIV-1 controllers and 24 responses in HIV-1 non-controllers were titrated and the SD50% compared between the two groups, showing a significantly higher functional avidity in the controllers (p = 0.0051, Mann Whitney). (**B**) Responses to 17 different optimally defined CTL epitopes located in beneficial, neutral and non-beneficial OLP were titrated in samples from 78 HIV infected individuals with variable viral load and disease status. The median SD50% (ng/ml) was defined for each epitope and compared to the OLP-specific protective ratio (Spearman Rank test, p = 0.0020). (**C**) Ten individuals who mounted responses to well-defined optimal CTL epitopes located in beneficial as well as in non-beneficial clade B OLP were identified and their responses titrated. The SD50% for responses detected in the same individual were compared (Wilcoxon matched pairs test, p = 0.0039). (**D**) In-vitro viral replication inhibition assays \[[@B48]\] were performed using a Nef modified and Raltegravir resistant test virus and purified CTL effector populations from the same individual targeting beneficial and non-beneficial OLP. One representative experiment of three assays conducted in different individuals is show. Levels of Gag p24 were determined after 4 days of co-culture of effector cells and auologous CD4 T cells used as target cells. Target cells were stimulated 3 days prior with dual-specific anti-CD3/8 mAb and infected at a MOI of 0.1. The negative control contained wells with target cells only (\"no CD8\").](1479-5876-9-208-5){#F5}

To more directly assess whether responses to beneficial OLP were of particularly high functional avidity, regardless of HIV controller status, we determined SD50% of responses to 17 optimal epitopes from beneficial, neutral and non-beneficial OLP (Figure [5B](#F5){ref-type="fig"}). Median epitope-specific SD50% were determined from an average of 7 titrations per epitope and compared to the OLP specific PR. A strongly significant, negative association between the PR and the SD50% was noted (p = 0.002, r = -0.69), indicating that beneficial OLP are targeted by high-avidity responses. To control for inter-individual differences due to disease status and viral load, we identified 10 individuals who targeted optimal epitopes in beneficial and non-beneficial OLP and determined their functional avidity. As in the cross-sectional analysis before, this matched comparisons showed in all cases a higher functional avidity for the epitopes located in the beneficial OLP compared to the responses targeting non-beneficial OLP (Figure [5C](#F5){ref-type="fig"}, p = 0.0020). Lastly, to relate the higher functional avidity to potential superior anti-viral effects in vivo, the ability to inhibit in vitro viral replication was assessed in three individuals who mounted robust responses against both beneficial and non-beneficial OLP. The in vitro inhibition assay first developed by Yang et al \[[@B48]\], was modified so that the NL4-3 based test virus contained a single nucleotide mutation in Nef (M20A) that blocks the Nef-mediated down-regulation of HLA class I molecules as well as two mutations in the integrase gene that mediate Raltegravir-resistance to permit the suppression of potentially replicating autologous virus in the assay. Indeed, CTL specific for the beneficial OLP(s) were up to 2 logs more effective inhibiting viral replication than CTL targeting non-beneficial OLP (Figure [5D](#F5){ref-type="fig"}), in line with recent data demonstrating different suppressive ability of HIV-1 specific CTL populations targeting Gag and Env-derived epitopes \[[@B24]\]. Although the in vitro inhibition assays were limited to few individuals with suitable response patterns, these data together with the results from the extensive titration assays in Figure [5B](#F5){ref-type="fig"} and [5C](#F5){ref-type="fig"} indicate that responses to beneficial OLP are of particularly high functional avidity and inhibit in vitro viral replication more effectively than responses to non-beneficial OLP. Of note, higher avidity responses to beneficial OLP compared to non-beneficial OLP were seen in all 10 tested individuals, ruling out that inter-individual variability in viral loads, duration of infection and HIV disease status could have biased the analyses.

Conclusions
===========

Defining functional correlates of HIV-1 immune control is critical to the design of effective immunogens. T cell responses to specific HIV-1 proteins and protein-subunits have been associated before with relatively superior viral control in vivo \[[@B14],[@B16],[@B49]\], but evidence from recent clinical trials suggests that including maximal immunogen content into various vectors does not necessarily induce more effective CTL responses \[[@B50],[@B51]\]. In fact, it has been argued that the existence of potential \"decoy\" epitopes may divert an effective CTL response towards variable and possibly less effective targets in the viral genome \[[@B52]\]. Thus, the definition of a minimal yet sufficient immunogen sequence that can elicit CTL responses in a broad HLA context is urgently needed. Thereby, focusing vaccine responses on conserved regions could help induce responses towards mutationally constrained targets and provide the basis for protection from heterologous viral challenge.

We present here the results of an extensive analysis that included more than 950 HIV-1 infected individuals with diverse HLA genotypes, from three different continents and including clade B and C infections. In both, the analysis in clade B in Lima and clade C in Durban, individual OLP were identified that are predominantly targeted by individuals with reduced or elevated viral loads, although the different size of the cohorts required different statistical approaches for their identification. In general, most of these OLP were among the more frequent targets in the HIV proteome, possibly due to both, the need for sizable responder groups to achieve statistical significance in the viral loads comparison as well as the high epitope density in these OLP. The identified OLP were frequently located in HIV-1 Gag and Pol, but rarely in the more variable proteins such as Env and Nef. With one exception, Nef and Env featured only non-beneficial OLP, thus arguing against their inclusion, at least as full proteins, in a CTL immunogen sequence \[[@B16]\]. In addition, in both cohorts, the Vif protein yielded few, yet exclusively beneficial OLP, which may warrant a renewed look at the inclusion of regulatory proteins in vaccine design \[[@B53],[@B54]\]. Also common to both clades, (and despite the wide scatter possibly due to the inclusion of less-frequently targeted OLP), an negative correlation between sequence entropy and PR was observed providing strong rationale for vaccine approaches that focus on conserved viral regions where T cell escape may be complicated by structural constrains \[[@B55]\]. This was particularly evident in the clade C cohort, where even within the relatively conserved Gag protein, a lower entropy was seen for the beneficial OLP compared to the remainder of the OLP spanning the protein. On the other hand, while beneficial and non-beneficial OLP showed a significant difference in their median entropy in the clade B cohort, this comparison was not significant in the clade C cohort. It is possible that the immunogen sequence, designed in 2001, did not optimally cover the circulating viral population in Durban throughout the enrollment period (until 2006), leading to missed responses particularly in the more variable segments of the virus \[[@B32],[@B56]\]. The study may have thus failed to identify beneficial as well as non-beneficial OLP in the more variable genes of HIV. This should have preferentially affected highly variable OLP due to a more frequent mismatch between autologous viral sequence and in vitro test set in these regions. However, even if scoring as beneficial OLP, such high-entropy OLP may from an immunogen-design point of view be of less interest as they would possible contribute only little to protection from heterologous viral challenge. It needs however also to be considered that the OLP-specific entropy values are based on variable numbers of sequences in the Los Alamos HIV database covering the different OLP, introducing potential further bias into these analyses, particularly for less covered proteins such as Vpu and other viral protein products. Such differences between autologous viral sequences and in vitro test sets may also have impacted the assessment of functional avidities. These determinations included responses in the same individual towards epitopes located in beneficial and non-beneficial OLP; with the former overall being more conserved. Thus, the higher functional avidity towards epitopes located in beneficial OLP could be biased by the higher chance that these epitopes matched the autologous viral sequence compared to epitopes located in non-beneficial OLP and which may thus have induced a more robust, avid response. Apart from covering autologous sequences, future studies will ideally also include comparable analyses in individuals identified and tested in acute infection that go on to control the infection at undetectable levels of viral replication (i.e. elite-controllers) so that the selective early emergence of responses to beneficial OLP could be linked to relative control of viral replication in chronic infection. As is, the identified beneficial responses may be particularly important to maintain low viral replication in chronic stages of infection, which in theory could be different (for instance due to more accelerated intra-individual viral evolution in variable genes) from responses determining viral set point during acute infection. However, the existing HLA bias in such cohorts and the small number of responses identified during earliest stages of infection may make such analyses a formidable undertaking that will require large numbers of individuals to be tested longitudinally.

A broadly applicable T cell immunogen sequence should include T cell targets restricted by a wide array of HLA class I alleles. Although broad representation of HLA-B alleles may be particularly important in this regard, emerging data on the effects HLA-C alleles in these cohorts may warrant a broad HLA-C representation as well \[[@B2],[@B47],[@B57]\]. In the present study, the 26 beneficial OLP from Lima and the 22 beneficial OLP from Durban covered 26 described, optimally defined CTL epitopes restricted by 20 different HLA alleles for the clade B cohort and 33 epitopes presented by 34 alleles for the clade C cohort, respectively \[[@B44]\]. As this is likely to be an underestimate of the true diversity in HLA restriction (Table [2](#T2){ref-type="table"} and ref \[[@B58]\]), it is reasonable to predict that the inclusion of identified beneficial OLP, or even a subset thereof, could evoke potential responses in a widely diverse HLA context. This could also provide the basis for the induction of poly-specific T cell responses with increased breath, which the present data clearly associates with progressively lower viral loads and which emerge as a potentially important parameter from several recent vaccine studies showing superior protection from SIV challenge in animals with a broad vaccine induced responses to Gag p17 \[[@B59],[@B60]\].

Recent studies have suggested a global adaptation of HIV-1 to its various host ethnicities \[[@B4],[@B46]\]. The consequence of such adaptation has led in some cases to the elimination of protective CTL targets, causing a profound absence of responses to these epitopes and detrimentally changing the association between HLA allele and HIV-1 disease outcome \[[@B4]\]. It is thus not surprising that the two main cohorts tested here yielded only partially overlapping sets of beneficial OLP as the impact of host genetics and viral evolution in the studied populations cannot readily be overcome. In fact, given studies by Frahm et al \[[@B4]\], the past and current adaptation of HIV-1 to common HLA class I alleles will likely still call for somewhat population tailored vaccine approaches, especially if the immunogen sequences should be kept short to avoid regions of potentially reduced immunological value \[[@B52]\]. Such approaches will also profit from more extensive structural analyses that may identify specific domains of viral proteins that are or are not enriched in valuable T cell targets; of which the latter could possibly be ignored for the design of T cell immunogen sequences. Additional analyses in other genetically unrelated cohorts of HIV-1 infected individuals and studies in SIV infection may further help to guide such selective immunogen design and to understand the factors defining the effectiveness of different epitopes in mediating relative HIV-1 control. Of note, the beneficial OLP identified here, 24 in clade B and 22 in clade C infection matched other immunogen design based on conserved elements in some parts as well, i.e. of the 14 conserved elements proposed by Hanke et al, eight (57%) overlapped at least partly with beneficial OLP identified here \[[@B61]\]. Similarly, among the highly conserved elements proposed by Rolland et al \[[@B52]\], 35% (5/14) were covered by our beneficial OLP in clade B infection. These differences possibly emerge because the present analysis is based on functional T cell data rather than viral sequence alignments, which may not take into consideration epitope density and processing preferences of certain regions. Nevertheless, the partial overlap with these other immunogen design support the focus on conserved regions and offers the opportunity for alternative or combined vaccine approach that elicit responses to regions where the virus is and possibly remains vulnerable \[[@B4],[@B46],[@B55],[@B62]\].

Finally, we used the extensive data set available to approach the question of relative effects of host genetics (i.e. HLA) and CTL specificity on HIV-1 control. While the two factors cannot be entirely disentangled, our data suggest that CTL specificity has an at least equal if not stronger effect on viral control than HLA class I allele expression. These findings are also in line with data by Mothe et al \[[@B63]\] showing that targeting key regions in p24 surrounding the dominant epitopes restricted by known protective alleles (KK10 for HLA-B27 and TW10 for HLA-B57/58) in HLA-B27, -57 or B58 negative individuals is associated with significantly reduced viral loads. In addition, the presence of individuals not expressing known beneficial alleles in HIV-1 elite controller cohorts \[[@B64]\], further indicates that HIV-1 control is not necessarily bound to a few specific HLA class I alleles. A detailed study of the total HIV-1-specific CTL response of subjects not expressing these alleles yet effectively controlling HIV-1 can be expected to provide further and crucially needed insight into the importance of targeting specific (conserved) regions of the viral genome for HIV-1 control. Similarly, the characterization of functional attributes of these responses, including functional avidity and the ability to suppress *in vitro*viral replication will need to be further assessed in such individuals. Building on experimentally derived and potentially promising immunogen sequences as defined here may thus provide a suitable basis for further immunogen design and iterative clinical trials in the human setting.
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